PMID- 3135955
OWN - NLM
STAT- MEDLINE
DCOM- 19880909
LR  - 20190510
IS  - 0143-3334 (Print)
IS  - 0143-3334 (Linking)
VI  - 9
IP  - 8
DP  - 1988 Aug
TI  - Modulation of chrysarobin skin tumor promotion.
PG  - 1445-50
AB  - The present study examined the effect of several prototypic inhibitors of phorbol 
      ester skin tumor promotion on skin tumor promotion by chrysarobin, an anthrone 
      tumor promoter. Retinoic acid (RA) inhibited skin tumor promotion by chrysarobin; 
      however, the degree of inhibition was dependent on the treatment protocol. When 
      RA (10 micrograms/mouse) was given 1 h after each twice-weekly application of 
      chrysarobin (220 nmol/mouse), a marked inhibition of papilloma formation was 
      observed (78%). In additional experiments, using a once-weekly application of 
      chrysarobin, RA also inhibited skin tumor promotion but the magnitude of 
      inhibition was less. Interestingly, RA (10 micrograms/mouse), given 1 or 6 h 
      after the promoter, did not inhibit the induction of epidermal ornithine 
      decarboxylase (ODC) activity induced by a single topical application of 
      chrysarobin (220 nmol). Fluocinolone acetonide (1 microgram/mouse), given 5 min 
      before each twice-weekly application of chrysarobin (220 nmol/mouse) effectively 
      inhibited skin tumor promotion (88%). A 0.5 or 0.25% supplement of 
      alpha-difluoromethylornithine (alpha-DFMO) in the drinking water inhibited the 
      induction of epidermal ODC following chrysarobin (220 nmol/mouse) treatment by 85 
      or 70%, respectively. Supplements of both 0.25 and 0.5% of alpha-DFMO also led to 
      a 50 and 61% inhibition, respectively, in the number of papillomas per mouse 
      after 25 weeks of promotion with chrysarobin. Interestingly, 0.25% alpha-DFMO in 
      the drinking water did not reduce the number of papillomas per mouse after 20 
      weeks of promotion with 1.7 nmol 12-O-tetradecanoylphorbol-13-acetate (TPA). 
      However, the number of papillomas per mouse that were greater than or equal to 4 
      mm in diameter was significantly reduced in both chrysarobin- and TPA-treated 
      mice. The data indicate that RA, FA and alpha-DFMO may be general inhibitors of 
      tumor promoter regardless of the chemical class of tumor promoter. The ability of 
      these inhibitors of phorbol ester promotion to inhibit anthrone promotion 
      indicates that some common biochemical pathways may exist for both classes of 
      skin tumor promoters.
FAU - DiGiovanni, J
AU  - DiGiovanni J
AD  - University of Texas System Cancer Center, Smithville 78957.
FAU - Kruszewski, F H
AU  - Kruszewski FH
FAU - Chenicek, K J
AU  - Chenicek KJ
LA  - eng
GR  - CA 37111/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Carcinogenesis
JT  - Carcinogenesis
JID - 8008055
RN  - 0 (Anthracenes)
RN  - 0 (Carcinogens)
RN  - 0CD5FD6S2M (Fluocinolone Acetonide)
RN  - 5688UTC01R (Tretinoin)
RN  - 6307EF51M1 (chrysarobin)
RN  - EC 4.1.1.17 (Ornithine Decarboxylase)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
RN  - ZQN1G5V6SR (Eflornithine)
SB  - IM
MH  - Animals
MH  - Anthracenes/*toxicity
MH  - *Carcinogens
MH  - Cocarcinogenesis
MH  - Eflornithine/pharmacology
MH  - Female
MH  - Fluocinolone Acetonide/pharmacology
MH  - Mice
MH  - Ornithine Decarboxylase/biosynthesis
MH  - Papilloma/chemically induced
MH  - Skin/enzymology
MH  - Skin Neoplasms/*chemically induced/prevention & control
MH  - Tetradecanoylphorbol Acetate
MH  - Tretinoin/pharmacology
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
AID - 10.1093/carcin/9.8.1445 [doi]
PST - ppublish
SO  - Carcinogenesis. 1988 Aug;9(8):1445-50. doi: 10.1093/carcin/9.8.1445.